{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T17:26:59Z","timestamp":1767374819628},"reference-count":16,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,4,15]],"date-time":"2016-04-15T00:00:00Z","timestamp":1460678400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Reports"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1016\/j.ekir.2016.04.002","type":"journal-article","created":{"date-parts":[[2016,4,30]],"date-time":"2016-04-30T12:06:45Z","timestamp":1462018005000},"page":"24-33","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Determination of Etelcalcetide Biotransformation and Hemodialysis Kinetics to Guide the Timing of Its Dosing"],"prefix":"10.1016","volume":"1","author":[{"given":"Katheryne Z.","family":"Edson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin M.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abhinaya","family":"Iyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Goodman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary L.","family":"Skiles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raju","family":"Subramanian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ekir.2016.04.002_bib1","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1185\/03007995.2015.1031731","article-title":"A\u00a0randomized, double-blind, phase 2 study evaluating the safety and efficacy of AMG 416 for the treatment of secondary hyperparathyroidism in hemodialysis patients","volume":"31","author":"Bell","year":"2015","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.ekir.2016.04.002_bib2","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/ndt\/gft417","article-title":"Velcalcetide (AMG 416), a\u00a0novel peptide agonist of the calcium-sensing receptor, reduces serum parathyroid hormone and FGF23 levels in healthy male subjects","volume":"29","author":"Martin","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2016.04.002_bib3","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/ki.2013.289","article-title":"AMG 416 (velcalcetide) is a novel peptide for the treatment of secondary hyperparathyroidism in a single-dose study in hemodialysis patients","volume":"85","author":"Martin","year":"2014","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2016.04.002_bib4","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1124\/jpet.113.204834","article-title":"Pharmacology of AMG 416 (Velcalcetide), a novel peptide agonist of the calcium-sensing receptor, for the treatment of secondary hyperparathyroidism in hemodialysis patients","volume":"346","author":"Walter","year":"2013","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.ekir.2016.04.002_bib5","doi-asserted-by":"crossref","first-page":"913","DOI":"10.2215\/CJN.06040710","article-title":"Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options","volume":"6","author":"Cunningham","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2016.04.002_bib6","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1124\/mol.115.098392","article-title":"Critical cysteine residues in both the calcium-sensing receptor and the allosteric activator AMG 416 underlie the mechanism of action","volume":"88","author":"Alexander","year":"2015","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.ekir.2016.04.002_bib7","doi-asserted-by":"crossref","DOI":"10.1124\/dmd.115.068007","article-title":"Nonclinical pharmacokinetics disposition, and drug-drug interaction potential of a novel D-amino acid peptide agonist of the calcium sensing receptor AMG 416 (etelcalcetide) [e-pub ahead of print]","author":"Subramanian","year":"2016","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.ekir.2016.04.002_bib8","series-title":"Sulphur-Containing Functional Groups","first-page":"634","article-title":"Thiol-disulfide interchange","author":"Singh","year":"1993"},{"key":"10.1016\/j.ekir.2016.04.002_bib9","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1053\/ajkd.2002.34918","article-title":"Osteocalcin and myoglobin removal in on-line hemodiafiltration versus low- and high-flux hemodialysis","volume":"40","author":"Maduell","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2016.04.002_bib10","unstructured":"Fresenius Optiflux\u00ae Dialyzers. Fresenius Medical Care North America, Waltham, MA; 2011. Available at: http:\/\/fmcna-dialyzers.com\/dialyzers-site\/pdf\/Optiflux Product Brochure Section\/101046-01 Optiflux High Flux.pdf. Accessed December 14,\u00a02015."},{"key":"10.1016\/j.ekir.2016.04.002_bib11","series-title":"ADAPT 5 User\u2019s Guide: Pharmacokinetic\/Pharmacodynamic Systems Analysis Software","author":"D\u2019Argenio","year":"2009"},{"key":"10.1016\/j.ekir.2016.04.002_bib12","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1093\/clinchem\/24.11.1895","article-title":"Additive, multiplicative, and mixed analytical errors","volume":"24","author":"Werner","year":"1978","journal-title":"Clin Chem"},{"key":"10.1016\/j.ekir.2016.04.002_bib13","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/chem.200305343","article-title":"Theoretical insights into the mechanism for thiol\/disulfide exchange","volume":"10","author":"Fernandes","year":"2004","journal-title":"Chemistry"},{"key":"10.1016\/j.ekir.2016.04.002_bib14","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1492-7535.2005.01138.x","article-title":"Hemodialysis adequacy: basic essentials and practical points for the nephrologist in training","volume":"9","author":"Depner","year":"2005","journal-title":"Hemodial Int"},{"key":"10.1016\/j.ekir.2016.04.002_bib15","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1002\/jcph.460","article-title":"Population pharmacokinetics analysis of AMG 416, an allosteric activator of the calcium-sensing receptor, in subjects with secondary hyperparathyroidism receiving hemodialysis","volume":"55","author":"Chen","year":"2015","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.ekir.2016.04.002_bib16","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1177\/0091270006293751","article-title":"Clearance of imidapril, an angiotensin-converting enzyme inhibitor, during hemodialysis in hypertensive renal failure patients: comparison with quinapril and enalapril","volume":"47","author":"Tsuruoka","year":"2007","journal-title":"J\u00a0Clin Pharmacol"}],"container-title":["Kidney International Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024916300031?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024916300031?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,19]],"date-time":"2020-09-19T08:34:15Z","timestamp":1600504455000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468024916300031"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["S2468024916300031"],"URL":"https:\/\/doi.org\/10.1016\/j.ekir.2016.04.002","relation":{},"ISSN":["2468-0249"],"issn-type":[{"value":"2468-0249","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Determination of Etelcalcetide Biotransformation and Hemodialysis Kinetics to Guide the Timing of Its Dosing","name":"articletitle","label":"Article Title"},{"value":"Kidney International Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2016.04.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Amgen Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}